Examine National Characteristics & Outcome Measures of GERD Patients Using the PPI Acid Suppression Symptom (PASS) Test for Response

Phase 4CompletedNCT00392002

AstraZeneca2,000 enrolled

Overview

To characterize the burden of disease in GERD patients of prescription therapy'

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

2,000

Conditions

Gastroesophageal Reflux

Interventions

EsomeprazoleDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Signed informed consent, 18 years or older, diagnosis of GERD Exclusion Criteria: * Peptic ulcer disease, upper gastrointestinal surgery, malignancy

Locations (2)

Research Site

Mississauga, Ontario, Canada

Research Site

Toronto, Ontario, Canada

Outcomes

Primary Outcomes

To compare the improvement in burden of overall GERD symptoms after 4 weeks of treatment with Esomeprazole verses maintenance of current therapy in subjects with persistent GERD symptoms.

Secondary Outcomes

To examine the relationship of the severity and frequency of GERD symptoms to treatment, at national, and regional levels.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.